Der Fäkale Mikrobiomtransfer: Mehr als nur ein Trend – Zeit für ein kritisches Hinterfragen

• Literatur

• 1 Manthey CF, Epple HJ, Keller KM. et al. S2k-Leitlinie Gastrointestinale Infektionen der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2024; 62: 1090-1149
• 2 Mullish BH, Merrick B, Quraishi MN. et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficileinfection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2024; 73: 1052-1075
• 3 Zikou E, Koliaki C, Makrilakis K. The Role of Fecal Microbiota Transplantation (FMT) in the Management of Metabolic Diseases in Humans: A Narrative Review. Biomedicines 2024; 12: 1871
• 4 Yadegar A, Bar-Yoseph H, Monaghan TM. et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev 2024; 37: e0006022
• 5 Zeissig S, Frost F, Haller D. et al. Die Rolle des Darm-Mikrobioms bei Entzündung und Krebs. Dtsch Arztebl Int. 2025;
• 6 DeLeon O, Mocanu M, Tan A. et al. Microbiome mismatches from microbiota transplants lead to persistent off-target metabolic and immunomodulatory effects. Cell 2025; 188: 3927-3941.e13
• 7 Kumar R, Yi Nm Zhi D. et al. Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile. NPJ Biofilms Microbiomes 2017; 3: 12
• 8 Aggarwala V, Mogno I, Li Z. et al. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nat Microbiol 2021; 6: 1309-1318
• 9 Bajaj JS, Fagan A, Gavis EA. et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial. J Hepatol 2025; 83: 81-91